Tenaya Therapeutics
TNYA
Tenaya Therapeutics (TNYA) news
Recent news
Tenaya's TN-401 gets FDA RMAT designation for ARVC
AInvest Wire · Sep 14, 2026Tenaya Therapeutics granted U.S. FDA regenerative medicine advanced therapy (RMAT) designation for TN-401 for the treatment of PKP2-associated arrhythmogenic right ventricular cardiomyopathy
AInvest Wire · Sep 14, 2026Tenaya Therapeutics Q2 operating expenses USD 45.198 million
AInvest Wire · Aug 5, 2026Tenaya Therapeutics Q2 pretax profit USD -43.393 million
AInvest Wire · Aug 5, 2026Tenaya Therapeutics Q2 net income USD -43.393 million
AInvest Wire · Aug 5, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.